Altamira partial spin-off of Bentrio 1st step in transition to become ‘pure play’ RNA delivery

 

• Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ET
• Partial spin-off of Bentrio® business first step in transition to become ‘pure play’ RNA delivery company
• Transition expected to complete in 2024 through partnering of further legacy assets
• Spending levels and cash burn aligned with strategic repositioning and to decrease significantly in 2024  
• Free of financial debt following early repayment of convertible loan  
• Expects to regain full compliance with Nasdaq continued listing rules through reverse split

Altamira management will hold an investor teleconference on Monday, December 11, 2023, at 8:30 a.m. ET to discuss its investor and business update. Founder, Chairman, and CEO Thomas Meyer will deliver prepared remarks that will be available via teleconference or webcast with audio and presenter-controlled slides.

Event: Altamira Therapeutics Business Update Call
Date: Monday, December 11, 2023
Time: 8:30 a.m. ET (5:30 a.m. PT)

Webcast URL: https://edge.media-server.com/mmc/p/k7s8zdkg

Register for Teleconference:

• Online:  https://register.vevent.com/register/BIc43c7804270544c6bac8d34949816636
• Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
• Select a method for joining the call.
• A dial-in number and unique PIN are displayed to connect directly from your phone.
• Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a US number.

A replay of the call will be available after the live event and accessible through the webcast link: https://edge.media-server.com/mmc/p/k7s8zdkg

https://www.globenewswire.com/news-release/2023/12/11/2793828/0/en/Altamira-Therapeutics-Provides-Investor-and-Business-Update.html